As the pharmaceutical landscape shifts toward increasingly complex modalities, companies face mounting pressure to accelerate development through more integrated approaches. OneSource’s “DNA to Device” model addresses this need by unifying drug substance, drug product, and device development within a single, cohesive quality framework. By eliminating fragmented handovers and aligning teams across the entire development lifecycle, this end-to-end CDMO solution reduces operational friction, compresses timelines, and enhances speed-to-clinic. Join this session as we discuss case study examples which demonstrate how parallel development strategies and platform-based processes can further accelerate readiness, enabling sponsors to move from concept to clinical execution with greater efficiency and confidence.
Check out the incredible speaker line-up to see who will be joining Kamal.
Download The Latest Agenda